Bioprocessing Venture, Innovation & Partnering Conference
(生物加工風險投資、創新與合作會議)

生物加工領域的創新與投資

2024年8月21日(EDT)


第二屆年度生物加工風險投資、創新與合作會議將匯聚推動未來生物加工發展的主要投資者、創新者、製造商和供應商。本次合作會議將有投資公司、生物製藥製造商、CDMO、醫療設備供應商以及創新型初創企業參與,討論生物加工創新面臨的最重要且最及時的挑戰。同時,還將探討推動這些創新的大型/中小型製藥公司及其風險投資部門的戰略,並分享在生物製藥及細胞與基因治療領域活躍的CEO和投資者的案例。 這種獨特組合的會議將為與會者帶來極具啟發性的全新視野。此外,參會者還可以在展示廳參觀眾多公司,親身體驗業界發展的方向。

8月21日 星期三

8:00 am

Registration and Networking Coffee

8:30 am

Organizer's Welcome Remarks

Nandini Kashyap, M.Pharm., Senior Director, Conferences and Social Media Strategy, Cambridge Innovation Institute

8:35 am

Co-Chairperson's Opening Remarks

Ran Zheng, CEO, Landmark Bio

8:40 am

Presentation to be Announced (Market Overview Opportunity Available)

9:00 am
PANEL DISCUSSION:

Investor Panel: Investment Trends in Life Science Industrial Innovation

PANEL MODERATOR:

Ann Lee, PhD, CTO, Prime Medicine, Inc.

In the rapidly evolving field of life sciences, understanding investment trends is crucial for both investors and innovators. This panel will bring together industry leaders to discuss the current state of investment in life science industrial innovation, focusing on bioprocessing and biomanufacturing. We will explore how these sectors are driving investment, highlighting the key trends and technologies that are capturing investor interest. The session will highlight discussion and insights around the topic such as:

  • Has the investment market rebounded, and what is its forecast?
  • What is being invested in and why?
  • When to invest in an innovative/disruptive technology? What do you look for?
  • How are changes in the global environment affecting the market and investment strategies?
  • What can start-ups do to move the needle on valuation of their company?
  • What to raise, when to raise, and how to raise, along with what to spend capital on post-raise
  • Lessons learned and best practices for investors and start-ups 
PANELISTS:

David Q. Anderson, General Partner, Ampersand Capital Partners

Philip Vanek, CTO, Gamma Biosciences

Alex De Winter, PhD, Vice President New Ventures, Danaher Corp.

Chenny Zhang, Director, Cerberus Ventures

9:40 am
PANEL DISCUSSION:

Exit Strategies: M&A vs. IPO Debate

PANEL MODERATOR:

Peter Lee, Partner, Avant Bio

Exit strategy is always important to consider, but particularly so in today's market environment. Both the capital markets and buyer landscape are shifting in the bioprocessing space, and it is critical to understand the impact of this evolution on exit strategies to best optimize outcomes. This panel will bring together leaders in the industry to discuss considerations around IPO vs. M&A and share perspectives on exit strategies more broadly. Topics to be discussed include:

  • The current state of the capital markets 
  •  Buyer landscape evolution 
  •  When does an IPO make sense and what are the factors to consider? 
  •  When does M&A make sense and what are the factors to consider? 
  •  Company perspective: IPO readiness and life as a public company + challenges of acquisition and integration 
  •  Lessons learned and current perspectives
PANELISTS:

Audrey Greenberg, Founder & Officer, CBM, SK pharmteco

Bryan Kipp, Senior Vice President, Technology and Licensing, Revvity, Inc.

Prem Tumkosit, Managing Director, Global Health Innovation Fund, Merck & Co.

Christian Uhrich, Investment Director, Biotechnology Investments, M Ventures

10:20 am

Presentation to be Announced (Market Overview Opportunity Available)

10:30 am

Networking Coffee Break

11:10 am
KEYNOTE FIRESIDE CHAT:

Life Science Executive

Konstantina Katcheves, Senior Vice President, Business Development, Alliance Management and Acquisitions, Teva Pharmaceuticals

11:40 am
KEYNOTE PRESENTATION:

Technology & Investment Trends in Genomic Medicine (tentative title)

Emmanuel Abate, President Genomic Medicine & Head, Sustainability, Cytiva Europe GmbH

12:00 pm

Networking Lunch

1:20 pm

Co-Chairperson's Remarks

Ann Lee, PhD, CTO, Prime Medicine, Inc.

1:25 pm
PANEL DISCUSSION:

AI & Technology Panel: Navigating Innovation, Technological Advancements, and Evolving Regulations

PANEL MODERATOR:

Lori Ellis, Head of Insights, BioSpace

The life sciences industry is transforming with advancements in artificial intelligence (AI). This panel will explore AI innovation, regulatory frameworks, and technological advancements in bioprocessing and drug development. Key discussions will cover AI's role in data management, process optimization, quality control, and operational efficiency, as well as regulatory challenges and opportunities. We will also examine the implications of the Loper Bright decision, which may allow courts to overturn FDA regulations, and the US-EU collaborative efforts to evaluate AI technologies.

Takeaways 

  • Emerging AI tools and platforms 
  •  Real-time monitoring and predictive maintenance 
  •  AI-driven workflow optimization and cost reduction 
  •  Regulatory frameworks for AI in bioprocessing 
  •  How the Loper Bright decision affects the FDA and HHS guidance regarding AI 
  •  Navigating the existing while preparing for both the EU AI Act and the US AI regulations to evolve 
  •  Future trends and breakthroughs in AI
PANELISTS:

Sherrine M. Eid, Global Head, Real World Evidence & Epidemiology, SAS Institute, Inc.

Sarah Glaven, Principal Assistant Director, Biotechnology and Biomanufacturing, White House Office of Science and Technology Policy

Nagisa Sakurai, PhD, Senior Investment Manager, Astellas

Cenk Ündey, VP, Global Head of Pharmaceutical Technical Development Data and Digital, , Roche

Micheal Walker, Executive Director - Life Sciences Supply Chain, Microsoft

Colin Zick, Partner, Foley Hoag LLP

2:15 pm
PANEL DISCUSSION:

How CEOs Are Navigating the Ups and Downs during Uncertain Times

PANEL MODERATOR:

Ran Zheng, CEO, Landmark Bio

This panel brings together industry leaders to delve into the strategic decisions and adaptive measures taken by CEOs in the CDMO sector. Focused on navigating through market shifts, regulatory challenges, and technological advancements, the discussion aims to uncover key insights into maintaining resilience, fostering innovation, and delivering operational agility amidst volatility. The panelists will share their experiences, perspectives, and foresight on steering their organizations through dynamic and complex business landscapes to achieve sustainable growth and industry leadership.

  • What key strategies were employed to navigate market volatility in the CDMO sector?
  • How do you balance short-term pressures with long-term strategic goals during uncertain times?
  • What regulatory challenges you have faced and what strategies were used to adapt to them?
  • How has technology played a role in a company’s ability to innovate and stay competitive?
  • How do you identify and capitalize on emerging market opportunities amidst uncertainty?
  • Measures to implement to build and maintain resilience within your organization? 
  •  How do you integrate new technologies into your existing workflows without disrupting operations? 
  •  Ways to foster a culture of innovation within your company during times of volatility? 
  •  How do you keep your team motivated in the face of challenges and create growth opportunities for key talent?
PANELISTS:

Steven J. Favaloro, President & CEO, Genezen

Patrick Lucy, President and CEO, RoslinCT

Rahul Singhvi, PhD, Co-Founder & CEO, Resilience

3:05 pm

Networking Refreshment Break

4:05 pm
PANEL DISCUSSION:

CDMO Panel: Advancing Collaborations and Partnerships

PANEL MODERATOR:

Gil Y Roth, President, PBOA Pharma & BioPharma Outsourcing Association

The role of the CDMO has transformed from lifecycle management to being a key contributor to a drug's development and commercialization. With geopolitical tensions, new modalities, supply chain issues, drug shortages, regulatory requirements, M&A, and other factors at play, how will CDMOs and their partners rise to the post-pandemic challenge? This discussion will center on how clients large and small can optimize their CDMO strategies, work with their partners more effectively, and adapt to the rapidly changing biopharma R&D environment.

Takeaways:

  • Understanding the CDMO ecosystem
  • Relying on trusted partners while keeping supply chain transparency
  • Leveraging CDMO expertise to advance pipelines
  • Staying on top of industry-shifting trends like onshoring & the rise of GLP-1s
PANELISTS:

Kerstin Dolph, Senior Vice President, Manufacturing, Charles River Laboratories

Robert Hughes, Global Head of Technical Operations, Galapagos

Ulrike Lemke, Business Unit President, Sterile Fill & Finish, Recipharm AG

4:45 pm

Co-Chairperson's Closing Remarks

Ran Zheng, CEO, Landmark Bio

5:00 pm
Networking Reception in the Exhibit Hall with Poster Viewing
6:00 pm
Close of Day

* 活動內容有可能不事先告知作更動及調整。

Virtual Event 通行證的申請已經結束。
On-Demand only通行證依然持續接受申請。
請透過以下詢問按鍵與我們聯絡。

Choose your language
Chinese
Japanese
Korean
English